A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Save

Date Added
April 21st, 2017
PRO Number
Pro00062582
Researcher
Ria Gripaldo
Keywords
Immune System, Inflammation, Lung, Pulmonary, Shortness of Breath
Summary

This study is being done to see how well the study drug, called nintedanib, may help your lung disease and to compare safety and effects of nintedanib with a placebo in participants with Progressive Firbrosing Interstitial Lung Disease (PF-ILD).

Institution
Palmetto
Recruitment Contact
Ria Gripaldo
803-434-3800
ClinicalTrialSurvey@PalmettoHealth.org

Boehringer Ingelheim Trial No. 1199.214: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ?Systemic Sclerosis associated Interstitial Lung Disease'(SSc-ILD) Save

Date Added
August 19th, 2016
PRO Number
Pro00050358
Researcher
Ria Gripaldo
Keywords
Lung, Scleroderma
Summary

Systemic Sclerosis is a devastating disease with unknown cause. No approved treatment is available. This is a double blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of oral nintedanib for 52 weeks in patients with Systemic Sclerosis associated Interstitial Lung Disease.

Institution
Palmetto
Recruitment Contact
Alisha Henderson
803-545-5453
alisha.henderson@uscmed.sc.edu

Change_preferences

-- OR --

Create_login